Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latiglutenase for Well-Controlled Celiac Disease (CeliacShield)
NCT03585478Phase 2Completed
- Start
- Mar 2019
- Primary completion
- Jan 2021
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of latiglutenase in celiac disease. Started Mar 2019; status: completed.
02
Drugs
latiglutenase
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT03585478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585478.